Personalized treatment strategies in glioblastoma: MGMT promoter methylation status.

摘要: The identification of molecular genetic biomarkers considerably increased our cur - rent understanding glioma genesis, prognostic evaluation, and treatment planning. In glio- blastoma, the most malignant intrinsic brain tumor entity in adults, promoter methylation status gene encoding for repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) indicates efficacy current standard care, which is concomitant adjuvant chemoradiotherapy with alkylating agent temozolomide. elderly, MGMT has recently been introduced to be a predictive biomarker that can used stratification regimes. This review gives short summery epide miological, clinical, diagnostic, aspects patients who are currently diagnosed glioblastoma. important markers epigenetic alterations glioblastoma summarized. Special focus given physiological function DNA particular, promoter, its clinical relevance, technical assessment, correlation mRNA protein expressions, place within management cascade patients.